ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	84.28	89.15	0.03	1.32	5.51
Revenue Growth (YoY)	-5.46%	297063.33%	-97.72%	-76.10%	-
Cost of Revenue	20.42	0.98	-	-	-
Gross Profit	63.86	88.17	-	-	-
Selling, General & Admin	230.12	71.68	47.28	18.46	4.69
Research & Development	13.18	19.58	20.27	18.38	20.27
Total Operating Expenses	243.3	91.26	67.55	36.83	24.96
Operating Income	-179.45	-3.08	-67.52	-35.52	-19.45
Interest Income	10.67	11.37	-	-	-
Interest Expense	-2.6	-	-	-	-
Other Non-Operating Income (Expense)	8.07	11.37	13.16	0.83	-0.79
Total Non-Operating Income (Expense)	16.14	22.74	13.16	0.83	-0.79
Pretax Income	-163.31	19.66	-54.37	-34.68	-20.24
Provision for Income Taxes	-0.08	0.29	-	-	-
Net Income	-171.3	8	-54.37	-34.68	-20.24
Net Income to Common	-171.3	8	-54.37	-34.68	-20.24
Shares Outstanding (Basic)	99	97	95	40	29
Shares Outstanding (Diluted)	99	102	95	40	29
Shares Change (YoY)	-3.74%	7.54%	138.30%	38.39%	893.01%
EPS (Basic)	-1.74	0.08	-0.57	-0.87	-0.70
EPS (Diluted)	-1.74	0.08	-0.57	-0.87	-0.70
Shares Outstanding	99.29	97.95	96.41	93.94	35.08
Free Cash Flow	-171.21	12.99	-59.44	-40.28	-17.62
Free Cash Flow Per Share	-1.74	0.13	-0.62	-1.01	-0.61
Gross Margin	75.77%	98.90%	100.00%	100.00%	100.00%
Operating Margin	-212.92%	-3.46%	-225066.67%	-2698.78%	-353.32%
Profit Margin	-203.25%	8.97%	-181216.67%	-2635.41%	-367.65%
FCF Margin	-203.14%	14.57%	-198136.67%	-3060.56%	-319.94%
EBITDA	-178.08	-3	-67.45	-35.48	-19.24
EBITDA Margin	-211.30%	-3.37%	-224823.33%	-2696.20%	-349.46%
EBIT	-179.45	-3.08	-67.52	-35.52	-19.45
EBIT Margin	-212.92%	-3.46%	-225066.67%	-2698.78%	-353.32%
Effective Tax Rate	0.05%	1.47%	0.00%	0.00%	0.00%

Updated Mar 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q